Company / R&D Expense
Integra Lifesciences Holdings R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$99.0M
FY2025
5-year range
$93.1M / $115.4M
FY2021-FY2025
Trend
-14.2%
vs FY2024
Sector context
#58 of 110
Health Care
What the data says
At $99M, Integra Lifesciences Holdings's r&d expense ranks #58 of 110 in the Health Care sector. R&D Expense has fluctuated over the past 10 years, ranging from $44M in FY2016 to $115M in FY2024.
Based on SEC 10-K filings.
$99M in FY2025 with a 5-year CAGR of +5.0%.
Declined from $104M to $99M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -0.7%
- 5-Year CAGR
- +5.0%
- 10-Year CAGR
- -
Sector benchmark
#58 of 110 in Health CareTop 53% of 110This company $99.0M Sector average $298.2M
▼
-66.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +5.0%, indicating consistent growth.
- In FY2025, r&d expense decreased 14.2% year-over-year.
- Ranks #58 out of 110 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.44 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $99.0M | -14.2% |
| FY2024 | $115.4M | +10.7% |
| FY2023 | $104.2M | +3.0% |
| FY2022 | $101.2M | +8.8% |
| FY2021 | $93.1M | +20.3% |
| FY2020 | $77.4M | -2.8% |
| FY2019 | $79.6M | +2.0% |
| FY2018 | $78.0M | +53.3% |
| FY2017 | $50.9M | +16.8% |
| FY2016 | $43.6M | -14.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026